BeiGene (BGNE)
(Delayed Data from NSDQ)
$172.85 USD
+1.82 (1.06%)
Updated May 17, 2024 04:00 PM ET
After-Market: $172.84 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BGNE 172.85 +1.82(1.06%)
Will BGNE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BGNE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BGNE
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
BGNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Top 5 Momentum Picks for January After a Fabulous 2023
New Strong Buy Stocks for December 22nd
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
Other News for BGNE
BeiGene initiated with bullish view at Bocom
BeiGene (BGNE) Shares Cross Above 200 DMA
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Sanara MedTech (SMTI)
BeiGene Performance Analysis: A Hold Rating with Cautious Optimism Amidst Competitive Pressures
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024